Department of Pharmaceutics, AISSMS College of Pharmacy, Pune 410001, Maharashtra, India.
Pharm Dev Technol. 2011 Oct;16(5):449-56. doi: 10.3109/10837450.2010.485319. Epub 2010 May 21.
Targeted delivery systems for the treatment of Inflammatory bowel disease (IBD) are designed to increase local tissue concentrations of anti-inflammatory drugs from lower doses compared with systemic administration. The objective of this study was to formulate and evaluate an oral system designed to achieve site-specific and instant drug release in the colon for effective treatment of IBD.
The system consists of a core tablet containing the model drug diclofenac sodium, superdisintegrant sodium starch glycolate, and coated with enteric polymer Eudragit FS 30 D to achieve different total percentage weight gain. Drug release studies were carried out using a changing pH method. A placebo formulation containing barium sulphate in the tablet was administered to human volunteers for in vivo X-ray studies. SEM studies were performed to determine coating thickness and film topography.
In vitro studies revealed that the tablet with 10% coating level released the drug after 5 h lag time corresponding to the colonic region. Tablets with 10% coating level could maintain their integrity in human volunteers for 5 h, approximating colon arrival time and release the drug instantaneously.
Colon-targeting and instant drug release for 10% coating level was due to the dissolution of the Eudragit FS 30 D and the immediate release effect of superdisintegrant. It was observed that as the coating level increased, the lag time also increased. This was because of increased diffusion path length and tortuosity at higher coating levels.
An in vivo-in vitro study revealed that not only the sensitivity of the polymer to the pH environment but also the thickness of coating plays an important role in colon delivery and the tablet with 5% superdisintegrant and 10% coating level achieved the desired performance of the colon targeting.
为了治疗炎症性肠病(IBD),靶向递药系统旨在通过与全身给药相比,从较低剂量下增加局部组织中抗炎药物的浓度。本研究的目的是设计和评估一种口服系统,以实现在结肠部位的局部和即时药物释放,从而有效治疗 IBD。
该系统由包含模型药物双氯芬酸钠、超级崩解剂交联聚维酮和肠溶聚合物 Eudragit FS 30D 的核心片剂组成,以达到不同的总增重百分比。采用变 pH 法进行药物释放研究。将含有片剂中硫酸钡的安慰剂制剂给予人类志愿者进行体内 X 射线研究。通过 SEM 研究来确定涂层厚度和膜形貌。
体外研究表明,含有 10%包衣水平的片剂在 5 小时的滞后时间后释放药物,这对应于结肠区域。含有 10%包衣水平的片剂可以在人类志愿者体内保持完整性 5 小时,接近结肠到达时间并立即释放药物。
10%包衣水平的结肠靶向和即时药物释放是由于 Eudragit FS 30D 的溶解和超级崩解剂的即刻释放作用。观察到随着包衣水平的增加,滞后时间也增加。这是因为在更高的包衣水平下,扩散路径长度和曲折度增加。
体内-体外研究表明,不仅聚合物对 pH 环境的敏感性,而且涂层的厚度在结肠递药中起着重要作用,并且含有 5%超级崩解剂和 10%包衣水平的片剂实现了结肠靶向的期望性能。